ATE396742T1 - Komplexe mit adjuvanter wirkung - Google Patents

Komplexe mit adjuvanter wirkung

Info

Publication number: ATE396742T1
Authority: AT; Austria
Prior art keywords: complexes; cancer; substance; activity against; pharmacological activity
Prior art date: 2004-01-07

Application number

AT05701809T

Other languages

English (en)

Inventor

Sunil Shaunak

Stephen Brocchini

Antony Godwin

Ji-Won Choi

Original Assignee

Polytherics Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-01-07

Filing date

2005-01-07

Publication date

2008-06-15

2005-01-07 Application filed by Polytherics Ltd filed Critical Polytherics Ltd

2008-06-15 Application granted granted Critical

2008-06-15 Publication of ATE396742T1 publication Critical patent/ATE396742T1/de

Links

239000002671 adjuvant Substances 0.000 title 1
206010028980 Neoplasm Diseases 0.000 abstract 2
239000000427 antigen Substances 0.000 abstract 2
102000036639 antigens Human genes 0.000 abstract 2
108091007433 antigens Proteins 0.000 abstract 2
201000011510 cancer Diseases 0.000 abstract 2
230000036039 immunity Effects 0.000 abstract 2
230000001939 inductive effect Effects 0.000 abstract 2
244000052769 pathogen Species 0.000 abstract 2
230000000144 pharmacologic effect Effects 0.000 abstract 2
239000000126 substance Substances 0.000 abstract 2
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 abstract 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
230000002163 immunogen Effects 0.000 abstract 1
229920000642 polymer Polymers 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Tropical Medicine & Parasitology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Biotechnology (AREA)
AIDS & HIV (AREA)
Ophthalmology & Optometry (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT05701809T 2004-01-07 2005-01-07 Komplexe mit adjuvanter wirkung ATE396742T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0400264.8A GB0400264D0 (en)	2004-01-07	2004-01-07	Complexes

Publications (1)

Publication Number	Publication Date
ATE396742T1 true ATE396742T1 (de)	2008-06-15

Family

ID=31503533

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05701809T ATE396742T1 (de)	2004-01-07	2005-01-07	Komplexe mit adjuvanter wirkung

Country Status (10)

Country	Link
US (1)	US20090176866A1 (de)
EP (1)	EP1701741B1 (de)
JP (1)	JP2007518732A (de)
CN (1)	CN1909928B (de)
AT (1)	ATE396742T1 (de)
AU (1)	AU2005203908B2 (de)
DE (1)	DE602005007177D1 (de)
ES (1)	ES2308432T3 (de)
GB (1)	GB0400264D0 (de)
WO (1)	WO2005065712A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0316294D0 (en)	2003-07-11	2003-08-13	Polytherics Ltd	Conjugated biological molecules and their preparation
GB0722080D0 (en) *	2007-11-09	2007-12-19	Polytherics Ltd	Novel complexes and a process for their preparation
AU2009270405B2 (en)	2008-06-30	2014-06-05	Esbatech, An Alcon Biomedical Research Unit Llc	Functionalized polypeptides
EP2769711A1 (de)	2008-07-10	2014-08-27	ESBATech, an Alcon Biomedical Research Unit LLC	Verfahren und Zusammensetzungen zur verstärkten Freisetzung von Makromolekülen
GB201210358D0 (en) *	2012-06-12	2012-07-25	Polytherics Ltd	Complexes
BR112018076015A8 (pt)	2016-06-17	2022-06-28	Sanofi Pasteur	Formulações imunogênicas compreendendo adjuvantes de polímero do ácido poliacrílico linear ou ramificado .

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5160737A (en) *	1988-05-03	1992-11-03	Perio Products Ltd.	Liquid polymer composition, and method of use
US5130126A (en) *	1990-07-09	1992-07-14	Nippon Oil & Fats Co., Ltd.	Polymer-drug conjugate and a method of producing it
JP3180106B2 (ja) *	1990-10-24	2001-06-25	株式会社三和化学研究所	有機高分子化合物の製造方法
DE4337945A1 (de) *	1993-11-06	1995-05-11	Labtec Gmbh	Pflaster zur Behandlung von Nagelmykosen
GB2290707A (en) *	1994-06-28	1996-01-10	Georgi Stankov	Pharmaceutical uses of Amphotericin B
CA2299117A1 (en) *	1999-02-24	2000-08-24	Stiefel Research Institute, Inc.	Antimycotic compositions
AU7025600A (en) *	1999-09-08	2001-04-10	School Of Pharmacy, University Of London, The	Uniform molecular weight polymers
MY129765A (en) *	2000-12-19	2007-04-30	Wyeth Corp	Improved mycoplasma hyopneumoniae bacterin vaccine
US20020176841A1 (en) *	2001-03-19	2002-11-28	Praecis Pharmaceuticals Inc.	Pharmaceutical formulations for sustained release
BR0105500A (pt) *	2001-11-05	2004-06-22	Univ Minas Gerais	Processo de obtenção de dispersões coloidais de anfotericina b; composições à base de anfotericina b de uso enteral, parenteral e tópico; uso destas composições no tratamento de micoses sistêmicas e infecções parasitárias

2004
- 2004-01-07 GB GBGB0400264.8A patent/GB0400264D0/en not_active Ceased
2005
- 2005-01-07 ES ES05701809T patent/ES2308432T3/es not_active Expired - Lifetime
- 2005-01-07 EP EP05701809A patent/EP1701741B1/de not_active Expired - Lifetime
- 2005-01-07 WO PCT/GB2005/000039 patent/WO2005065712A2/en not_active Ceased
- 2005-01-07 US US10/585,286 patent/US20090176866A1/en not_active Abandoned
- 2005-01-07 AU AU2005203908A patent/AU2005203908B2/en not_active Ceased
- 2005-01-07 CN CN2005800020894A patent/CN1909928B/zh not_active Expired - Fee Related
- 2005-01-07 JP JP2006548383A patent/JP2007518732A/ja active Pending
- 2005-01-07 DE DE602005007177T patent/DE602005007177D1/de not_active Expired - Lifetime
- 2005-01-07 AT AT05701809T patent/ATE396742T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
ES2308432T3 (es)	2008-12-01
GB0400264D0 (en)	2004-02-11
JP2007518732A (ja)	2007-07-12
DE602005007177D1 (de)	2008-07-10
CN1909928B (zh)	2011-01-12
EP1701741A2 (de)	2006-09-20
US20090176866A1 (en)	2009-07-09
AU2005203908B2 (en)	2011-02-03
AU2005203908A1 (en)	2005-07-21
WO2005065712A2 (en)	2005-07-21
WO2005065712A3 (en)	2006-04-27
CN1909928A (zh)	2007-02-07
EP1701741B1 (de)	2008-05-28

Legal Events

Date	Code	Title	Description
2008-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
CY1120070T1 (el)	2018-12-12	Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
CY1113190T1 (el)	2016-04-13	Μεθοδος αγωγης της αιμολυτικης νοσου
TR200103018T2 (tr)	2002-02-21	İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
CY1113984T1 (el)	2016-07-27	Προϊοντα συζευξης μεϋτανσινοειδους dm1 με αντισωμα trastuzumab, συνδεδεμενα μεσω μη-διασπασιμου συνδετηρα και χρηση αυτων στη θεραπεια ογκων
CY1122817T1 (el)	2021-05-05	Νεα αντι-il 13 αντισωματα και χρησεις αυτων
CY1119029T1 (el)	2018-01-10	Θεραπευτικη αντιμετωπιση συμπαγων εγκεφαλικων νεοπλασιων με ενα παραγωγο ραπαμυκινης
CY1119906T1 (el)	2018-06-27	Πολυμερικες συζευξεις οπιοειδων ανταγωνιστων
NO20014491D0 (no)	2001-09-14	Fremgangsmåte
CY1118668T1 (el)	2017-07-12	Ανοσοσυζευγματα εναντι υποδοχεα φολικου οξεος 1 και χρησεις αυτων
ATE478867T1 (de)	2010-09-15	Substituierte quinazolinone verbindungen
BRPI0518104B8 (pt)	2021-05-25	artigo industrializado e uso de anticorpo her2
CY1112458T1 (el)	2015-12-09	Ενα αντισωμα ειδικο για διαλυτο baff για χρηση στην αντιμετωπιση του καρκινου
MX340017B (es)	2016-06-22	Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
IS6667A (is)	2003-01-02	Aðferðir til að meðhöndla gigtarsjúkdóma með því að nota leysanlega CTLA4 sameind
MX2023013995A (es)	2024-02-06	Conjugados de anticuerpo y antraciclina.
TR200102969T2 (tr)	2002-08-21	Siklik protein tirozin kinaz önleyicileri.
TR199901949T2 (xx)	2000-01-21	Lemfositik t�m�rler i�in �areler.
CY1110162T1 (el)	2015-01-14	Φαρμακοτεχνικη μορφη και μεθοδοι για την αγωγη της θρομβοκυτταραιμιας
WO2006020722A3 (en)	2007-02-08	Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
ATE528319T1 (de)	2011-10-15	Krebsbehandlung mit anti-il-1-antikörpern
CY1109692T1 (el)	2014-08-13	Νεες ανοσοδραστικες συνθεσεις
CY1110341T1 (el)	2015-01-14	Παραγωγα κιναζολινης και η χρηση τους στην θεραπευτικη αγωγη θρομβοκυτταραιμιας
BR0010590A (pt)	2003-07-22	Emprego de filanto para estimulação objetivada do sistema imunológico
ATE458472T1 (de)	2010-03-15	In vivo targeting von dendritischen zellen
WO2013104050A3 (en)	2015-04-02	Methods of treating triple negative breast cancer and basal-like breast cancer using inhibitors against kidney associated 1 (kaag1) inhibitor